 |
|
|
| |
Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 datafrom the randomized, double-blind, Phase III ECHO and THRIVE trials
|
| |
| |
Reported by Jules Levin
CROI 2011 Feb 27-March 2 Boston
Jose Arribas,1 Jaime Andrade-Villanueva,2 Nick Bellos,3 Pedro Cahn,4 Christine Katlama,5 Jacob Lalezari,6 Kiat Ruxrungtham,7 David Wohl,8 Simon Vanveggel,9 Katia Boven10
1Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; 2Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; 3Southwest Infectious Disease Associates, Dallas, TX, USA; 4Hospital Juan A Fernandez and Fundacion Huesped, Buenos Aires, Argentina; 5Universite Pierre et Marie Curie, Paris VI and Hopital Pitie-Salpetriere, Paris, France; 6Quest Clinical Research, San Francisco, CA, USA; 7HIV-NAT, Thai Red Cross AIDS Research Centre and Chulalongkorn University Bangkok, Thailand; 8The Center for AIDS Research, The University of North Carolina at Chapel Hill, NC, USA; 9Tibotec BVBA, Beerse, Belgium; 10Tibotec Inc., Titusville, NJ, USA
|
| |
|
|
|
|
|
